As President and CEO of Sentrimed, Bill Ragatz has significant and broad commercial experience in addition to expertise in building strong organizations and successfully developing and launching pipeline assets. Bill has over 25 years of experience in the pharmaceutical/biotech industry. Most recently, Bill was SVP, Head of Commercial at Viela Bio, where he built and led the global commercial organization and created the overall commercial vision for bringing pipeline assets to market. Bill was integral to Viela’s IPO and its successful acquisition by Horizon Therapeutics. Throughout his career, Bill has led numerous product launches spanning a range of therapeutic areas, including oncology, respiratory, and cardiovascular disease. Bill earned his MBA from the Fuqua School of Business at Duke University.